Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Rubin

Showing results (81-90 of 566) with videos related to

Pageof 57
Sort By:
Gastroenterology|January 28, 2023
Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is It Ready for Standard Practice?Mariangela Allocca, Torsten Kucharzik, David T Rubin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 13, 2024
Impact of a health-system specialty pharmacy on time to upadacitinib initiationDavid Choi, David T Rubin, Bernice Man
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 2, 2025
ReplyAgnes H Y Ho, David T Rubin
Plos One|April 21, 2017
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesHaridarshan Patel, Trevor Lissoos, David T Rubin
Inflammatory Bowel Diseases|February 24, 2012
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims dataDavid T Rubin, Ozgecan Uluscu, Robert Sederman
ACG Case Reports Journal|November 7, 2024
Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaaDavid Choi, Benjamin McDonald, David T Rubin
Gastroenterology|September 25, 2021
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel DiseaseNathaniel A Cohen, Alexa Silfen, David T Rubin
The Annals of Pharmacotherapy|March 18, 2022
Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel DiseaseDavid K Choi, Archariya Puangampai, David T Rubin
Genetic Testing and Molecular Biomarkers|July 8, 2009
Genetic testing for inflammatory bowel disease: focus group analysis of patients and family membersJeffrey R Lewis, Vani Konda, David T Rubin
Gastroenterology & Hepatology|August 9, 2019
Treatment De-Escalation in Patients With Inflammatory Bowel DiseaseAmanda Israel, Katia El Jurdi, David T Rubin
Pageof 57

Showing results (81-90 of 566) with videos related to

Sort By:
Pageof 57
Gastroenterology|January 28, 2023
Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is It Ready for Standard Practice?Mariangela Allocca, Torsten Kucharzik, David T Rubin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 13, 2024
Impact of a health-system specialty pharmacy on time to upadacitinib initiationDavid Choi, David T Rubin, Bernice Man
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 2, 2025
ReplyAgnes H Y Ho, David T Rubin
Plos One|April 21, 2017
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesHaridarshan Patel, Trevor Lissoos, David T Rubin
Inflammatory Bowel Diseases|February 24, 2012
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims dataDavid T Rubin, Ozgecan Uluscu, Robert Sederman
ACG Case Reports Journal|November 7, 2024
Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaaDavid Choi, Benjamin McDonald, David T Rubin
Gastroenterology|September 25, 2021
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel DiseaseNathaniel A Cohen, Alexa Silfen, David T Rubin
The Annals of Pharmacotherapy|March 18, 2022
Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel DiseaseDavid K Choi, Archariya Puangampai, David T Rubin
Genetic Testing and Molecular Biomarkers|July 8, 2009
Genetic testing for inflammatory bowel disease: focus group analysis of patients and family membersJeffrey R Lewis, Vani Konda, David T Rubin
Gastroenterology & Hepatology|August 9, 2019
Treatment De-Escalation in Patients With Inflammatory Bowel DiseaseAmanda Israel, Katia El Jurdi, David T Rubin
Pageof 57